Research-grade compound. Laboratory use only. Not intended for human or animal use, ingestion, or injection. No medical claims are made or implied.
KPV
Purity is high at 98.786%, but this vial assayed 11.93 mg against a 10 mg label — 119.3% of the label claim, a 19.3% overfill.
Free shipping on orders over €200
- If a product doesn't match the specification on its published COA, contact us with your batch number: we investigate against the lot's report and replace any product that fails it, at no cost to you.
- Contact us within 48 hours of delivery with photos of the outer box, inner packing, and any affected vials with labels legible. Confirmed transit damage is replaced at no cost to you.
Purity is high at 98.786%, but this vial assayed 11.93 mg against a 10 mg label — 119.3% of the label claim, a 19.3% overfill.
3–7 days most of the EU · 10–14 Nordics/Baltics
Standard EU from €4.99 (RO) · core EU GLS €17.99 · Nordics/Baltics €12.99–€15.99 · Dispatched within 1–2 business days · Free shipping over €200.00 · no customs paperwork (EU) · via EU carrier network
€200.00 away from free shipping over €200.00. Under that, standard EU shipping is €17.99 (GLS, most of the EU).
How Paysera and SEPA work
- Pay: send a manual SEPA transfer using the IBAN we email you, or, where checkout offers it for your address, approve a SEPA transfer in your own bank via Paysera's hosted page.
- We confirm — Paysera notifies us instantly, or we match a manual transfer when it arrives (usually 1 business day).
- We dispatch — confirmed orders typically ship within 1–2 business days.
Card payments are not currently offered. There is no card processor on this checkout.
KPV is a naturally occurring tripeptide (Lys-Pro-Val) derived from the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH). It has been studied for its immunomodulatory signaling in gastrointestinal and immune biology research models. Alpha-MSH-derived immunomodulatory tripeptide Intestinal epithelial barrier and PepT1 transporter research NF-kB pathway modulation studies For research purposes only. Not for human consumption.
| Quantity | Price Each | Total | Savings |
|---|---|---|---|
| 1 unit | €31.49 | €31.49 | -- |
| 3+ | €29.92 | €89.75 | 5% off |
| 5+Most Popular | €28.34 | €141.70 | 10% off |
| 10+ | €26.77 | €267.66 | 15% off |
Important Notice
This product is intended for laboratory and research use only. Not for human or veterinary use. By purchasing, you confirm this product will be used exclusively for in-vitro research purposes.
Due to legal and regulatory requirements, this product cannot be shipped to: Croatia, Italy, Lithuania, and Slovenia.
Reconstitution Required
This peptide ships lyophilized (dry powder) and requires bacteriostatic water to reconstitute before use. BAC water is sold separately.
Recommended: BAC water · stable for 28 days at 2-8°C once mixed.
When This Product May Not Suit Your Research
- ⚠If your research requires GMP-grade material for clinical applications — research-grade peptides are not intended for clinical use.
- ⚠If your lab lacks proper cold storage (-20°C freezer) — this peptide's stability may be compromised at higher temperatures.
- ⚠If your study protocol requires FDA-approved reference standards — contact USP or a certified reference material provider.
Published laboratory reports are available for selected lots. Check each report for its result and stated method. For research purposes only.
View report #233644 on janoshik.com →
Dispatched within 1–2 business days, shipping from €4.99 in Romania, from €12.99 across the rest of Europe
Class-level specification on record; independent Janoshik report on selected lots
About KPV
KPV (Lys-Pro-Val) is a tripeptide derived from the C-terminus of alpha-melanocyte-stimulating hormone (alpha-MSH). This three-amino acid sequence retains the core anti-inflammatory activity of the parent molecule. Alpha-MSH is a POMC-derived neuropeptide known for its roles in pigmentation, energy balance, and inflammation suppression. The C-terminal KPV sequence was identified as the minimal active unit responsible for the anti-inflammatory effects.
In research models, KPV is studied for its activity through melanocortin receptors (particularly MC1R) and its direct anti-inflammatory activity in intestinal epithelial cells -- specifically suppressing NF-kB activation and downstream inflammatory cytokine production. This intestinal epithelial activity has made KPV particularly interesting for research into inflammatory bowel disease (IBD) models, where inflammation of the intestinal mucosal layer is the central pathology under study. Unlike the full alpha-MSH molecule, KPV is a small, stable tripeptide that can potentially survive GI transit and act locally on intestinal mucosa -- a useful delivery route to study for GI inflammatory pathways.
Specifications
| Parameter | Value |
|---|---|
| Compound | KPV (Lys-Pro-Val, alpha-MSH C-terminal tripeptide) |
| Purity | ≥98% (class-level specification) |
| Format | Lyophilized powder |
| Reconstitution | Sterile water or saline |
| Storage | -20°C; 2-8°C after reconstitution |
Storage
Store at -20°C before reconstitution. Refrigerate at 2-8°C after reconstitution and use within 28 days. KPV is a small, stable tripeptide with good shelf life under proper storage conditions.
How does KPV suppress inflammation?
In research models, KPV acts through melanocortin receptor 1 (MC1R) and through direct intracellular mechanisms in epithelial cells. It suppresses NF-kB nuclear translocation -- a critical step in the inflammatory signaling cascade -- and downstream production of pro-inflammatory cytokines including IL-6, IL-8, and TNF-alpha. In intestinal epithelial cell studies, KPV has been shown to reduce inflammatory cytokine production induced by bacterial components (LPS) and by cytokines like IL-1beta. The MC1R-mediated component adds an additional layer of anti-inflammatory signaling through cAMP pathway activation.
Why is KPV specifically studied for IBD rather than other inflammatory conditions?
KPV's intestinal epithelial cell activity and potential oral stability make it particularly suited for GI inflammatory research. IBD models (Crohn's disease, ulcerative colitis) involve inflammatory activation of intestinal mucosal cells, and local delivery of anti-inflammatory signals to these cells is a research goal. KPV's small size (tripeptide) gives it better potential for surviving GI transit than larger peptides, though stability is still formulation-dependent. Nanoparticle formulations for oral KPV delivery to the intestinal mucosa have been developed and studied in colitis models specifically for this reason.
How does KPV compare to full alpha-MSH for anti-inflammatory research?
Full alpha-MSH (13 amino acids) activates all five melanocortin receptors (MC1R-MC5R) including MC4R, which mediates GLP-1 receptor signalling and sexual effects in the hypothalamus. KPV retains the anti-inflammatory C-terminal activity with more selective receptor engagement and much smaller molecular size. For research specifically on the anti-inflammatory arm of alpha-MSH activity without confounding appetite/endocrine effects, KPV is a more tractable tool. The small size also makes it more amenable to oral delivery research for GI applications.
KPV is supplied for laboratory research use only. Not for human use. Handle in compliance with institutional biosafety guidelines.
Specification Summary
About KPV
KPV (Lys-Pro-Val) is a tripeptide derived from the C-terminus of alpha-melanocyte-stimulating hormone (alpha-MSH). This three-amino acid sequence retains the core anti-inflammatory activity of the parent molecule. Alpha-MSH is a POMC-derived neuropeptide known for its roles in pigmentation, energy balance, and inflammation suppression. The C-terminal KPV sequence was identified as the minimal active unit responsible for the anti-inflammatory effects.
In research models, KPV is studied for its activity through melanocortin receptors (particularly MC1R) and its direct anti-inflammatory activity in intestinal epithelial cells -- specifically suppressing NF-kB activation and downstream inflammatory cytokine production. This intestinal epithelial activity has made KPV particularly interesting for research into inflammatory bowel disease (IBD) models, where inflammation of the intestinal mucosal layer is the central pathology under study. Unlike the full alpha-MSH molecule, KPV is a small, stable tripeptide that can potentially survive GI transit and act locally on intestinal mucosa -- a useful delivery route to study for GI inflammatory pathways.
Specifications
| Parameter | Value |
|---|---|
| Compound | KPV (Lys-Pro-Val, alpha-MSH C-terminal tripeptide) |
| Purity | ≥98% (class-level specification) |
| Format | Lyophilized powder |
| Reconstitution | Sterile water or saline |
| Storage | -20°C; 2-8°C after reconstitution |
Storage
Store at -20°C before reconstitution. Refrigerate at 2-8°C after reconstitution and use within 28 days. KPV is a small, stable tripeptide with good shelf life under proper storage conditions.
How does KPV suppress inflammation?
In research models, KPV acts through melanocortin receptor 1 (MC1R) and through direct intracellular mechanisms in epithelial cells. It suppresses NF-kB nuclear translocation -- a critical step in the inflammatory signaling cascade -- and downstream production of pro-inflammatory cytokines including IL-6, IL-8, and TNF-alpha. In intestinal epithelial cell studies, KPV has been shown to reduce inflammatory cytokine production induced by bacterial components (LPS) and by cytokines like IL-1beta. The MC1R-mediated component adds an additional layer of anti-inflammatory signaling through cAMP pathway activation.
Why is KPV specifically studied for IBD rather than other inflammatory conditions?
KPV's intestinal epithelial cell activity and potential oral stability make it particularly suited for GI inflammatory research. IBD models (Crohn's disease, ulcerative colitis) involve inflammatory activation of intestinal mucosal cells, and local delivery of anti-inflammatory signals to these cells is a research goal. KPV's small size (tripeptide) gives it better potential for surviving GI transit than larger peptides, though stability is still formulation-dependent. Nanoparticle formulations for oral KPV delivery to the intestinal mucosa have been developed and studied in colitis models specifically for this reason.
How does KPV compare to full alpha-MSH for anti-inflammatory research?
Full alpha-MSH (13 amino acids) activates all five melanocortin receptors (MC1R-MC5R) including MC4R, which mediates GLP-1 receptor signalling and sexual effects in the hypothalamus. KPV retains the anti-inflammatory C-terminal activity with more selective receptor engagement and much smaller molecular size. For research specifically on the anti-inflammatory arm of alpha-MSH activity without confounding appetite/endocrine effects, KPV is a more tractable tool. The small size also makes it more amenable to oral delivery research for GI applications.
KPV is supplied for laboratory research use only. Not for human use. Handle in compliance with institutional biosafety guidelines.
What research shows
Selected peer-reviewed studies from the published literature. Each describes laboratory or preclinical findings and is attributed to the cited study, not to this product. For research use only — not medical guidance.
Intestinal inflammation
In in-vitro and murine research, PepT1-mediated uptake of the tripeptide KPV was reported to reduce intestinal inflammation.
PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology (2008). PMID: 18061177Inflammatory bowel disease models
In murine models of inflammatory bowel disease, the melanocortin-derived tripeptide KPV was studied for its anti-inflammatory potential.
Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases (2008). PMID: 18092346Keratinocyte signalling
In human keratinocyte cell-culture research, the alpha-MSH C-terminal fragment KPV was examined within melanocortin signalling pathways.
alpha-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells. Journal of Investigative Dermatology (2004). PMID: 15102092Citations are provided for research reference. CertaPeptides (CERTALAB S.R.L.) is a reseller, not a manufacturer, and makes no medical, therapeutic, or efficacy claims. Products are for laboratory research use only and are not for human or animal consumption.
Researcher Confidence
Why researchers choose CertaPeptides
Who actually tests this?
Selected lots are independently verified by Janoshik Analytical (Czech Republic) and published on the Janoshik public portal. Other lots ship with the supplier's batch specification. See /coa for the published wall.
View COAs →What if I get the wrong batch?
Every vial label carries a code. Look it up on our Verify page: it shows what CertaPeptides publishes for that code and, for a withdrawn lot, that the lot was withdrawn and why. If yours is withdrawn, or if the code on your label finds nothing, email us that code.
View COAs →Where does it ship from?
Romania (EU). We are CERTALAB SRL, CUI 54169956, VAT-registered. Sameday for Romania, GLS for most EU destinations, TCE Worldwide for the remaining cross-border EU and non-EU markets (UK, Switzerland). Delivery 1–15 business days depending on destination — exact window shown at checkout.
Shipping details →What if there's a problem?
You have a 14-day withdrawal right under OUG 34/2014 (Romanian/EU consumer law), with escalation to ANPC and alternative dispute resolution (SAL) available. Contact us at support@certapeptides.com.
Returns policy →Product Information
This product is intended for scientific research and development purposes only. It is a chemical substance that shall not be used as a drug, medicine, active substance, or ingredient in any product intended for human or animal consumption. Researchers must handle this compound in accordance with their institutional biosafety guidelines. Use only in properly equipped laboratory settings with appropriate personal protective equipment.
